InflaRx stops Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility, focusing on INF904 while maintaining GOHIBIC for COVID-19 treatment.
InflaRx stops Phase 3 trial for vilobelimab in pyoderma gangrenosum due to futility, focusing on INF904 while maintaining GOHIBIC for COVID-19 treatment.